Hematopoietic stimulation by amifostine and sodium phenylbutyrate: What is the potential in MDS?

Leukemia Research

Volumn 22, Issue SUPPL. 1, 1998, Pages

  List, Alan F ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Amifostine; Hematopoietic progenitor growth; Myeloid growth factors; Recombinant hematopoietic cytokines; Sodium phenylbutyrate

Indexed keywords

AMIFOSTINE; ARYLBUTYRIC ACID DERIVATIVE; RECOMBINANT CYTOKINE; SODIUM DERIVATIVE;

CELL DIFFERENTIATION; CONFERENCE PAPER; HEMATOPOIESIS; HUMAN; LEUKEMIA CELL; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL;

AMIFOSTINE; CELL DIFFERENTIATION; CLINICAL TRIALS; CYTOPROTECTION; HEMATOPOIESIS; HUMANS; MYELODYSPLASTIC SYNDROMES; PHENYLBUTYRATES; PRODRUGS;

EID: 0031818139     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(98)00034-4     Document Type: Conference Paper

References (40)

1. List AF, Garewal HS, Sandberg AA. The myelodysplastic syndromes: biology and implications for management [review]. J Clin Oncol 1990;8:1424.
2. Merchav S, Wagemaker G, Souza LM, Tatarsky I. Impaired response of myelodysplastic marrow progenitors to stimulation with recombinant haemopoietic growth factors. Leukemia 1991;5:340.
3. Hoefsloot LH, Vanamelsvoort MP, Breeders LCAM, Vanderplas DC, Vanlom K, Hoogerbrugge H, Touw IP, Lowenberg B. Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome. Blood 1997;89:1690.
4. Raza A, Gezer S, Mundle S, Gao XZ, Alvi S, Borok R, Rifkin S, Shetty V, Parcharidou A, et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995;86:268.
5. Miller KB, Kim K, Morrison FS, et al. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase III intergroup study - published erratum appears in Ann Hematol 1993. Ann Hematol 1992;65:162.
6. Rowinsky EK, Conley BA, Jones RJ, et al. Hexamethylene bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrations. Leukemia 1992;6:526.
7. Rowinsky EK, Donehower RC, Spivak JL, et al. Effects of the differentiating agent hexamethylene bisacetamide on normal and myelodysplastic hematopoietic progenitors. J Natl Cancer Inst 1990;82:1926.
8. Christman JK, Medelshon N, Herzog D, et al. Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukemic cells (HL-60). Cancer Res 1983;43:763.
9. Glover AB, Leyland-Jones BR, Chun HG, et al. Azacytidine: 10 years later. Cancer Treat Rep 1987;71:737.
10. Silverman LR, Holland JF, Weinberg RS, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 1993;7(1):21.
11. Leid M, Kastner P, Durand B, et al. Retinoic acid signal transduction pathways. Ann NY Acad Sci 1993;684:19.
12. Clark RE, Ismail SA, Jacobs A, et al. A randomized trial of 13-cis-retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndrome. Br J Haematol 1987;66:77.
13. Koeffler HP, Heitjan D, Mertelsmann R, et al. Randomized study of 13-cis-retinoic acid v placebo in the myelodysplastic disorders. Blood 1988;71:703.
14. Ohno R, Naoe T, Hirano M, et al. Treatment of myelodysplastic syndromes with all-trans retinoic acid (Leukemia Study Group of the Ministry of Health and Welfare). Blood 1993;81:1152.
15. Aul C, Runde V, Gattermann N. All-trans retinoic acid in patients with myelodysplastic syndromes: results of a pilot study. Blood 1993;82:2967.
16. Kurzrock R, Estey E, Talpaz M. All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome. J Clin Oncol 1993;11:1489.
17. Koeffler HP, Hirji K, Itri L. 125-Dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Rep 1985;69:67.
18. 3 for prolongation of leukemic transformation-free survival in myelodysplastic syndromes. Am J Hematol 1991;38:67.
19. 3. Am J Hematol 1986;23:175.
20. Perrine SP, Ginder GD, Faller GV, Dover DV, Ikuta T, Witkowska HE, Cai SP, Vichinsky EP, Olivieri NF. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. N Engl J Med 1993;328:81.
21. McCaffrey PG, Newsome DA, Fibach E, Yoshida M, Su MS. Induction of gamma-globin by histone deacetylase inhibitors. Blood 1997;90(5):2075.
22. Samid D, Shack S, Myers CE. Selective growth arrest and phenotypic conversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J Clin Invest 1993;91:2288.
23. Samid D, Ram Z, Hudgins WR, Shack S, Liu L, Walbridge S, Oldfild EH, Myers CE. Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. Cancer Res 1994;54:891.
24. Gore SD, Samid D, Weng LJ. Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation and apoptosis of primary neoplastic myeloid cells. Clin Cancer Res 1997;3:1755.
25. Pineau T, Hudgins WR, Liu L, Chen LC, Sher T, Gonzales FJ, Samid D. Activation of a human peroxisome-proliferator-activated receptor by the antitumor agent phenylacetate and its analogs. Biochem Pharmacol 1996;52:659.
26. Brusilow SW, Finkelstein J. Restoration of nitrogen homeostasis in a man with ornithine transcarbamylase deficiency. Metabolism 1993;42:1336.
27. Gore SD, Miller CB, Weng L-J, Burks K, Griffin CA, Chen T-L, Smith V, Birke PJ, Grever M, Rowinsky EK. Clinical development of sodium phenylbutyrate as a putative differentiating agent in myeloid malignancies. Anticancer Res 1997;17:3938a.
28. Calabro-Jones PM, Aguilera JA, Ward JF, Smoluk GD, Fahey RC. Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug. Cancer Res 1988;48:3634.
29. Glover D, Glick JH, Weiler C, Hurowitz S, Kligerman MM. WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial. J Clin Oncol 1986;4:584.
30. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D, Glick J. Amifostine pretreatment for protection against cyclophosphasmide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996;14:2107.
31. List AF, Heaton R, Glinsmann-Gibson B, Capizzi RL. Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity. Sem Oncol 1996;23:58.
32. List AF, Heaton R, Glinsmann-Gibson B, Capizzi RL. Amifostine stimulates formation of multipotent progenitors and generates macroscopic colonies in normal and myelodysplastic bone marrow. Proc Am Soc Clin Oncol 1996;15:449.
33. Klimecki W, Heaton R, Glinsmann-Gibson B, List A. Amifostine suppresses apoptosis in myelodysplastic CD34+ cells and promotes progenitor growth via polyamine-like effects. Blood 1997;80(1):520a.
34. Wyatt I, Moore RB, Smith LL. Competition for polyamine uptake into rat lung slices by WR2721 and analogues. Int J Radiat Biol 1989;55:463.
35. Meier T, Issels RD. Degradation of 2-(3-aminopropylamino)-ethanethiol (WR-1065) by Cu-dependent amine oxidases and influence on glutathione status of Chinese hamster ovary cells. Biochem Pharm 1995;50:489.
36. Holwitt EA, Koda E, Swenberg CE. Enhancement of topoisomerase I-mediated unwinding of supercoiled DNA by the radioprotector WR-33278. Radiat Res 1990;124:107.
37. Grdina DJ, Constantinou A, Shigematsu N, Murley JS. Inhibition of topoisomerase II alpha activity in CHO K1 cells by 2-[(aminopropyl)amino]ethanethiol (WR-1065). Radiat Res 1994; 138:44.
38. Sigdestad CP, Bergquist BL, Grdina DJ. The effect of chemical radiation protectors on cell cycle progression after gamma or neutron irradiation. Cell Prolif 1991;24:271.
39. Grdina DJ, Sigdestad CP. Chemical protection and cell-cycle effects on radiation-induced mutagenesis. Cell Prolif 1992;25:23.
40. List AF, Brasfield F, Heaton R, Glinsmann-Gibson B, Crook L, Taetle R, Capizzi R. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood 1997;90(9):3364.